BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

FDA began a safety review of Celgene's Revlimid lenalidomide after preliminary data from clinical trials showed a potential increased risk for secondary malignancies associated with the cancer drug. The agency said it currently believes the benefits of...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >